In June 2026, Mounjaro is named on 78.5% of UK private obesity clinic listings against Wegovy's 22.1%. In community pharmacies the two brands are level at roughly 24% each. Pooled across all 3,569 audited UK locations, Mounjaro leads Wegovy 1.7 to 1 on mention rate. Source: Rare.Monitor, June 2026.
Rare.Monitor audited 3,569 UK pharmacies and registered locations active in obesity treatments in June 2026. The cohort splits into 2,518 community pharmacies registered with the General Pharmaceutical Council and 1,051 non-GPHC registered private obesity clinics regulated by CQC (England), HIW (Wales), HIS (Scotland) or RQIA (Northern Ireland). For each location, the audit records whether the public-facing listing names a given obesity treatment brand.
How are Mounjaro and Wegovy named across UK pharmacy channels?
Brand mention rate is the percentage of locations in a cohort whose public-facing listing names a given brand. The audit reports three views: community pharmacies, private obesity clinics, and the pooled UK universe. Both Mounjaro (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk) carry NICE approval for managing overweight and obesity in adults meeting the relevant BMI and risk-factor criteria.
In GPHC-registered community pharmacies, Wegovy is named on 24.3% of listings and Mounjaro on 24.1%. The two brands sit level on this channel. In non-GPHC registered private obesity clinics, Mounjaro is named on 78.5% of listings and Wegovy on 22.1%. Pooled across the 3,569-location universe, Mounjaro leads Wegovy 1.7 to 1 on mention rate.
What does mention rate measure?
Mention rate measures the presence of a brand name on a location's public-facing listing. It does not measure the indication for which the brand is dispensed, prescribing intent, off-label use, the volume dispensed at any location, or the channel's current stock position. The metric is a presence signal, read alongside dispensing and distribution data rather than in place of either.
UK supply of GLP-1 obesity treatments was intermittently constrained between 2023 and 2025, tracked through national patient safety alerts on access and prescribing during that window. Some of the channel-level differences visible in June 2026 listings may reflect what each channel could reliably source over the preceding two years, rather than independent commercial preference. The audit reports presence on the listing as of June 2026; it does not reconstruct the supply or distribution position behind that listing.
For the per-brand top 10 ranking of UK community-pharmacy obesity treatments, see our companion brand analysis report. For the metric definitions and database scope used to produce both reports, see the brand analysis methodology.
Methodology. Mention Rate is the percentage of UK pharmacies and registered locations active in obesity treatments whose public-facing listing names an obesity treatment brand, calculated against the audited cohort. This article reports three views: 2,518 GPHC-registered community pharmacies, 1,051 non-GPHC registered private obesity clinics (CQC, HIW, HIS, RQIA), and the pooled 3,569-location UK universe. Mention Rate measures the presence of a brand name on a pharmacy or clinic listing only. It does not evidence the indication for which the brand is dispensed at each location, prescribing intent, off-label use, the volume dispensed, or the channel's stock position. The Semaglutide and Liraglutide rows in the underlying brand audit capture mentions of the international non-proprietary name where the listing did not name a Novo Nordisk brand specifically; compounded supply, where present, would sit in those rows. Source: Rare.Monitor, June 2026.
